March 26, 2010 - Posters will Illustrate Progress of Company’s Drugs for Metabolic and Endocrine Diseases – Versartis, Inc., an emerging biotechnology company developing novel biologics for the treatment of patients with metabolic diseases, will present two scientific posters that demonstrate monthly dosing capabilities of the company’s lead product, VRS-859 (exenatide-XTEN), and earlier stage product, VRS-317 (hGH-XTEN), at the 14th Annual International Congress on Endocrinology (ICE 2010) beginning today in Kyoto, Japan. Jeffrey Cleland, Ph.D., Founder and Chief Executive Officer of Versartis, said, “We are very encouraged by the potential of the novel XTEN technology to provide monthly dosing in preclinical studies. This new data validates our earlier research results and supports our plans for advancing both products into the clinic later this year.”
VRS-859, a once monthly dosage form of the GLP-1 analog exenatide, has demonstrated improved glycemic control over and comparable weight loss to an infusion of exenatide. VRS-859 is on track for a Phase 1a trial in type 2 diabetes patients to begin in the second quarter 2010. VRS-317, a once monthly dosage form of human growth hormone (hGH), has demonstrated superiority of dosing and tolerability over other long-acting hGH analogs... Versartis' Press Release -
